20 Aug SANSUM CLINIC RECOGNIZED AS an AXONICS® CENTER OF EXCELLENCE
Sansum Clinic received designation July 2020 as an Axonics Center of Excellence by Axonics Modulation Technologies, Inc. The designation recognizes Sansum Clinic’s Urology Department, specifically Dr. Alexandra Rogers, for her expertise with Axonics Therapy and her sincere commitment to treating debilitating incontinence symptoms. Millions of patients suffer from bladder and bowel dysfunction. 1 This evolved therapy option stimulates the sacral nerve to restore communication between the brain and the bladder. Dr. Rogers is the only urologist with fellowship training in voiding dysfunction in the Santa Barbara area and is the number one implantor of the Axonics device in California. “This sacral neuromodulation implant approved in just the last year is changing the landscape of how we treat and manage both urinary and fecal incontinence” reports Dr Rogers. “The efficacy can significantly improve quality of life with a patient management system that is user friendly.” In a clinical study, 129 patients with urgency incontinence were treated with Axonics Therapy. At 1-year, 89% of patients had successful therapy and 93% of patients were satisfied with their therapy.2
About Sansum Clinic
Since its founding in 1921, Sansum Clinic has been improving the overall health of its patients by providing the latest innovations in equipment, technology, procedures and treatments. Sansum Clinic is the largest independent nonprofit healthcare organization between the Los Angeles Basin and the San Francisco Bay Area. With more than 220 affiliated physicians, Sansum Clinic serves more than 130,000 patients (800,000) annually at our 22 patient care facilities in south Santa Barbara County. To learn more, please visit www.sansumclinic.org.
About Axonics Modulation Technologies, Inc. and Sacral Neuromodulation
Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. Axonics SNM therapy, which has been clinically proven to reduce symptoms and restore pelvic floor function, is now being offered at hundreds of medical centers across the U.S. and in dozens of select hospitals in Western Europe. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit www.axonics.com.
1. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132-1138.
2. Benson K, McCrery R, Taylor C, et al. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence. Neurourology and Urodynamics. 2020; 39:1482–1488.